Paris, April 24th, 2019 – 07:00 PM CET - Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, announces its Board of Directors, meeting today, has voted unanimously to appoint a new Chief Executive Officer to lead the next development phase of the Company and its Bionic Vision System PRIMA. The new CEO, agreed by the Board of Directors, will be appointed on May 13, 2019.
The Board of Directors has ended the mandate of Khalid Ishaque as Chief Executive Officer and acknowledged his commitment in leading the Company to the first successful implantations of PRIMA in human as well as building its awareness among key worldwide leaders in retinal diseases.
The Board of Directors asked its Chairman, Bernard Gilly, to fulfil the role of Chief Executive Officer of Pixium Vision on an interim basis with immediate effect. When new CEO joins the Company, governance will return to separate roles.
Bernard Gilly, Chairman of the Board of Directors of Pixium Vision, commented: “Building on the success of PRIMA’s first human results, Pixium Vision is entering a new phase of its development. The Company, now in a major moment of its history, needs to drive at best PRIMA’s development to the market, to anticipate its transition to growth thanks to its breakthrough technology and to increase its global visibility.”
| Pixium Vision |
Didier Laurens, CFO
+33 1 76 21 47 68
| Media contact |
Annie-Florence Loyer - email@example.com
+33 1 44 71 00 12 / +33 6 88 20 35 59
ABOUT PIXIUM VISION
Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Pixium Vision is in clinical stage with PRIMA, its sub-retinal miniature photovoltaic wireless implant system, designed for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.
| Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles. |
Pixium Vision is included in the Euronext CAC All Shares index Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP
This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.
For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company’s Registration Document filed with the AMF under number D.19-0364 on April 18, 2019 which can be found on the websites of the AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).